Thyroid UK is very pleased that the Competition and Markets Authority (CMA) has fined Advanz and others for hiking up the price of liothyronine by 6,000%. It has taken a long time for this to happen and we hope that it will send a message to other pharma companies that it is not right to increase the prices of drugs that are a lifeline for many patients.
I had a meeting with the CMA this morning and they told me that Advanz now have 8 weeks to put in an appeal, (which Advanz has already said they will be doing) although probably not until the very end of the 8 weeks. The CMA will then have 6 weeks to put in a defence.
They also gave me details of the Competition Appeal Tribunal website which is very transparent and where we will be able to see exactly what is happening once Advanz put in their appeal – catribunal.org.uk
The NHS can now, if they decide to, seek compensation for the firms’ behaviour, by way of damages. It will be very interesting to see what happens next.
So, this is by no means over but I think we can just about see the light at the end of the tunnel.